Management of Treatment-Experienced HIV-Infected Patients

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/21/21 (What's New)


  • Based on available data, the combination of lopinavir/ritonavir plus either NRTIs or twice-daily raltegravir can be used to successfully treat patients experiencing virologic failure of first-line NNRTI-based therapy
    • However, in clinical practice in the developed world it is more common for boosted darunavir or dolutegravir plus NRTIs to be used in this setting
    • Results from the DAWNING trial support the efficacy of dolutegravir plus 2 NRTIs after failure of a first-line regimen consisting of an NNRTI plus 2 NRTIs, with the caveat that in this study the second-line regimen was required to include at least 1 active NRTI by resistance testing

Action required